[en] Cytosolic caspase-8 is a mediator of death receptor signaling. While caspase-8 expression is lost in some tumors, it is increased in others, indicating a conditional pro-survival function of caspase-8 in cancer. Here, we show that tumor cells employ DNA-damage-induced nuclear caspase-8 to override the p53-dependent G2/M cell-cycle checkpoint. Caspase-8 is upregulated and localized to the nucleus in multiple human cancers, correlating with treatment resistance and poor clinical outcome. Depletion of caspase-8 causes G2/M arrest, stabilization of p53, and induction of p53-dependent intrinsic apoptosis in tumor cells. In the nucleus, caspase-8 cleaves and inactivates the ubiquitin-specific peptidase 28 (USP28), preventing USP28 from de-ubiquitinating and stabilizing wild-type p53. This results in de facto p53 protein loss, switching cell fate from apoptosis toward mitosis. In summary, our work identifies a non-canonical role of caspase-8 exploited by cancer cells to override the p53-dependent G2/M cell-cycle checkpoint.
Disciplines :
Biochimie, biophysique & biologie moléculaire
Auteur, co-auteur :
Muller, Ines
Strozyk, Elwira
Schindler, Sebastian
Beissert, Stefan
Oo, Htoo Zarni
SAUTER, Thomas ; University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit
Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28.
Date de publication/diffusion :
2020
Titre du périodique :
Molecular Cell
ISSN :
1097-2765
eISSN :
1097-4164
Maison d'édition :
Cell Press, Etats-Unis - Massachusetts
Peer reviewed :
Peer reviewed vérifié par ORBi
Focus Area :
Systems Biomedicine
Projet européen :
H2020 - 642295 - MEL-PLEX - Exploiting MELanoma disease comPLEXity to address European research training needs in translational cancer systems biology and cancer systems medicine
Projet FnR :
FNR7643621 - Predicting Individual Sensitivity Of Malignant Melanoma To Combination Therapies By Statistical And Network Modeling On Innovative 3d Organotypic Screening Models, 2013 (01/05/2015-30/04/2018) - Thomas Sauter
Organisme subsidiant :
CE - Commission Européenne
Commentaire :
Copyright (c) 2020 Elsevier Inc. All rights reserved.